STAMPEDE Trial Updates in Prostate Cancer - Silke Gillessen
December 5, 2018
(Length of Discussion: 12 min)
Silke Gillessen and Alicia Morgans discuss recent data from the STAMPEDE trial. Local radiotherapy improving survival in metastatic prostate cancer with low disease burden and the subanalysis looking at the effects of abiraterone acetate plus prednisone in both high and low metastatic hormone-sensitive prostate cancer. Silke shares the clinical trial design and data outcomes of the trial, summarizing the clinical implication.
Biographies:
Silke Gillessen, MD, Professor and Chair in Genitourinary Oncology Systemic Therapy Research at The University of Manchester and The Christie NHS Foundation Trust, Co-founder of the Advanced Prostate Cancer Consensus Conference (APCCC)
Alicia Morgans, MD, MPH
Silke Gillessen and Alicia Morgans discuss recent data from the STAMPEDE trial. Local radiotherapy improving survival in metastatic prostate cancer with low disease burden and the subanalysis looking at the effects of abiraterone acetate plus prednisone in both high and low metastatic hormone-sensitive prostate cancer. Silke shares the clinical trial design and data outcomes of the trial, summarizing the clinical implication.
Biographies:
Silke Gillessen, MD, Professor and Chair in Genitourinary Oncology Systemic Therapy Research at The University of Manchester and The Christie NHS Foundation Trust, Co-founder of the Advanced Prostate Cancer Consensus Conference (APCCC)
Alicia Morgans, MD, MPH
Related Content:
Radiotherapy to the Primary Tumour for Men with Newly-Diagnosed Metastatic Prostate Cancer: Survival Results from STAMPEDE
STAMPEDE - Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low-Risk Metastatic Hormone Sensitive Prostate Cancer
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Analysis of Abiraterone Acetate + Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-Naïve Prostate Cancer - Phase 3 LATITUDE Trial
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer